{"id":"W4399047717","doi":"10.17650/1726-9776-2024-20-1-24-35","title":"Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms","year":2024,"lang":"en","type":"article","venue":"Cancer Urology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University","funders":"","keywords":"Lenvatinib; Medicine; Sunitinib; Pembrolizumab; Renal cell carcinoma; Oncology; Internal medicine; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004151849,0.001403647,0.002897862,0.0004867047,0.0004917097,0.001054427,0.0008550472,0.001053471,0.002820228],"category_scores_gemma":[0.00151339,0.0005505599,0.003727955,0.0005355428,0.0007706512,0.001062823,0.0006997382,0.002492544,0.0006179776],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007522592,"about_ca_system_score_gemma":0.002188768,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008090676,"about_ca_topic_score_gemma":0.002583466,"domain_scores_codex":[0.9983271,0.000972914,0.00008931364,0.0002357755,0.0001936867,0.0001812995],"domain_scores_gemma":[0.9984647,0.0002071261,0.000413841,0.0001407204,0.0001074443,0.0006660796],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.931205,0.009964779,0.02212716,0.0005708773,0.004318489,0.00009453262,0.0001214832,0.001088233,0.009276332,0.000189843,0.002122346,0.01892098],"study_design_scores_gemma":[0.7059408,0.2058986,0.07733537,0.00006916121,0.002789537,0.0002663932,0.0001179931,0.001468277,0.001664622,0.0005035501,0.003888342,0.00005736609],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9880634,0.004026802,0.0004805249,0.0005324067,0.0001350319,0.002494112,0.002787214,0.00004229189,0.001438291],"genre_scores_gemma":[0.9837993,0.001447374,0.001449683,0.001123241,0.0003379774,0.004282668,0.006074653,0.00002966984,0.001455399],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004151849,"threshold_uncertainty_score":0.02195734,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02240287845722777,"score_gpt":0.3040383810767318,"score_spread":0.281635502619504,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}